We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

BioMérieux’s BIOFIRE Respiratory Panel 2.1 Plus with SARS-CoV-2 Receives CE Mark

By LabMedica International staff writers
Posted on 16 Jul 2020
Print article
Illustration
Illustration
BioMérieux’s (Marcy-l'Étoile, France) BIOFIRE Respiratory Panel 2.1 plus (RP2.1plus) is CE marked and will be commercially available in all countries that recognize CE marking.

The BIOFIRE RP2.1plus Panel is part of BioMérieux’s suite of products in response to the COVID-19 pandemic. The ARGENE SARS-CoV-2 R-GENE was launched in March 2020, followed by the US FDA EUA cleared BIOFIRE RP2.1 panel and the VIDAS anti-SARS- CoV-2 IgM and anti-SARS-CoV-2 IgG tests. The BIOFIRE Respiratory Panel 2.1 plus (RP2.1plus) tests for 23 pathogens (19 viruses, including SARS-CoV-2, and four bacteria) which are responsible for the most frequent respiratory tract infections. The new panel advances the existing BIOFIRE Respiratory Panel 2 plus (RP2plus) by adding SARS-CoV-2 to the panel menu while maintaining an assay runtime of about 45 minutes. It also includes an assay for the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The BIOFIRE Respiratory Panel 2.1 plus (RP2.1plus) allows healthcare providers to quickly identify patients with common respiratory pathogens and differentiate those with COVID-19, using one single test. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE FILMARRAY TORCH systems and is extremely easy to use.

“The availability of BIOFIRE RP2.1plus in all countries recognizing CE marking represents a global syndromic response to this unprecedented COVID-19 pandemic,” said Pierre Boulud, Chief Operating Officer, Executive Vice President, Clinical Operations at BioMérieux. “With increasing reagent production capacity and an installed base of more than 14 000 BIOFIRE units throughout the world, BIOFIRE RP2.1plus will play a key role now and in the upcoming respiratory season as healthcare providers face the regular group of respiratory pathogens as well as SARS-CoV-2.”

Related Links:
BioMérieux

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.